A Comparative Study of Platelet-Rich Plasma and Normal Saline Dressings in the Treatment of Chronic Wounds (PRP-NS Wound T) (PRP-NS Wound T)

A COMPARATIVE STUDY of PLATELET-RICH PLASMA and NORMAL SALINE DRESSINGS in the TREATMENT of CHRONIC WOUNDS

This study aims to compare the effectiveness of Platelet-Rich Plasma (PRP) dressings versus Normal Saline dressings in the treatment of chronic wounds. Chronic wounds are slow-healing wounds that can cause significant discomfort, increase the risk of infections, and impact a patient's quality of life.

Platelet-Rich Plasma (PRP) is derived from the patient's own blood and contains growth factors that may help promote faster wound healing. On the other hand, Normal Saline dressings are commonly used as a standard wound care approach.

Participants in this study will be randomly assigned to receive either PRP dressings or normal saline dressings. The healing progress of their wounds will be monitored over a specified period to determine which treatment leads to better and faster healing.

The findings from this study may help improve wound care management and provide evidence for using PRP as an effective treatment for chronic wounds.

Study Overview

• Status: Completed
• Conditions: Wound Healing
• Intervention / Treatment: Procedure: Platelet-Rich Plasma (PRP) Injections

• Study Type: Interventional
• Enrollment (Actual): 156
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Pakistan
  • Punjab
    • Bahawalpur, Punjab, Pakistan, 63100
      • Bahawal Victoria Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients aged 18-60 years of either gender were included if they had a chronic wound persisting for at least six weeks and with a size of at least 2 × 2 cm.

Exclusion Criteria:

• Patients were excluded if their wounds had existed for less than six weeks, if they had a previous history of PRP dressing use, or if they had documented hypersensitivity to PRP.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PRP Dressing Group; wounds were first cleaned with normal saline, followed by the injection of PRP, prepared from the patient's own blood by the hematology department, into the surrounding wound area twice weekly	Procedure: Platelet-Rich Plasma (PRP) Injections; wounds were first cleaned with normal saline, followed by the injection of PRP, prepared from the patient's own blood by the hematology department, into the surrounding wound area twice weekly
Active Comparator: Normal Saline Dressing Group	Procedure: Platelet-Rich Plasma (PRP) Injections; wounds were first cleaned with normal saline, followed by the injection of PRP, prepared from the patient's own blood by the hematology department, into the surrounding wound area twice weekly

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Wound Healing Rate	April 17, 2024, to October 16, 2024

Collaborators and Investigators

• Sponsor: Quaid-e-Azam Medical College

Study record dates

Study Major Dates

• Study Start (Actual): April 17, 2024
• Primary Completion (Actual): April 17, 2024
• Study Completion (Actual): April 17, 2024

Study Registration Dates

• First Submitted: February 8, 2025
• First Submitted That Met QC Criteria: February 24, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 24, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Wounds and Injuries
• Other Study ID Numbers: 2381/DME/QAMC Bahawalpur; 2381/DME/QAMC (Other Identifier: Department of medical education, QAMC Bahawalpur)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No